{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Myeloablative+Conditioning&page=15",
    "query": {
      "intervention": "Myeloablative Conditioning",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 467,
    "total_pages": 47,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Myeloablative+Conditioning&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Myeloablative+Conditioning&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T02:47:30.019Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00006458",
      "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "indium In 111 monoclonal antibody MN-14",
          "type": "RADIATION"
        },
        {
          "name": "yttrium Y 90 monoclonal antibody MN-14",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-03-03",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 1,
      "location_summary": "Belleville, New Jersey",
      "locations": [
        {
          "city": "Belleville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006458"
    },
    {
      "nct_id": "NCT03529825",
      "title": "Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Microbial Colonization"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 26,
      "start_date": "2018-07-18",
      "completion_date": "2021-09-10",
      "has_results": false,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03529825"
    },
    {
      "nct_id": "NCT03412877",
      "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endocrine Tumors",
        "Non-Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Gastrointestinal/Genitourinary Cancers",
        "Neuroendocrine Tumors",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Individual Patient TCR-Transduced PBL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA(R))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 285,
      "start_date": "2018-09-06",
      "completion_date": "2029-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03412877"
    },
    {
      "nct_id": "NCT00350181",
      "title": "Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma, Non-Hodgkin",
        "Hematologic Diseases",
        "Acute GVHD"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        },
        {
          "name": "BCNU",
          "type": "DRUG"
        },
        {
          "name": "VP-16",
          "type": "DRUG"
        },
        {
          "name": "CY",
          "type": "DRUG"
        },
        {
          "name": "FTBI",
          "type": "DRUG"
        },
        {
          "name": "BU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "2 Years to 60 Years"
      },
      "enrollment_count": 11,
      "start_date": "2006-08",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2021-09-23",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00350181"
    },
    {
      "nct_id": "NCT01183429",
      "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "3F8 and 13-cis-retinoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Months and older"
      },
      "enrollment_count": 39,
      "start_date": "2010-08-12",
      "completion_date": "2018-09-13",
      "has_results": true,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183429"
    },
    {
      "nct_id": "NCT00528437",
      "title": "Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumors"
      ],
      "interventions": [
        {
          "name": "temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 46,
      "start_date": "2005-10",
      "completion_date": "2017-12-30",
      "has_results": true,
      "last_update_posted_date": "2021-07-08",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Lihue, Hawaii + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lihue",
          "state": "Hawaii"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00528437"
    },
    {
      "nct_id": "NCT01700673",
      "title": "Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-06",
      "completion_date": "2020-06",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01700673"
    },
    {
      "nct_id": "NCT04774536",
      "title": "Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "CRISPR_SCD001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Walters, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 9,
      "start_date": "2025-08-22",
      "completion_date": "2030-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 3,
      "location_summary": "Davis, California • Los Angeles, California • Oakland, California",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04774536"
    },
    {
      "nct_id": "NCT06802315",
      "title": "Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia, Relapsed, Adult",
        "Acute Myeloid Leukemia Refractory",
        "Chronic Myeloid Leukemia - Accelerated Phase",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Intensity modulated total marrow irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Cyclophosphamide (CTX)",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine (Fludara)",
          "type": "DRUG"
        },
        {
          "name": "Busulfan (conditioning for ALLO Transplant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2025-02-04",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06802315"
    },
    {
      "nct_id": "NCT00714259",
      "title": "Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma",
        "CLL / SLL",
        "Non Hodgkin's Lymphoma",
        "Waldenstroms",
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Infusion of Stem Cells",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "19 Years to 70 Years"
      },
      "enrollment_count": 5,
      "start_date": "2008-07",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2017-07-24",
      "last_synced_at": "2026-10-25T02:47:30.019Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00714259"
    }
  ]
}